Emily Robb
Acute Care · Bakersfield, CANPI 1821495953
Payments from drug & device makers
Across 20 payments — averaging $153.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Organon$3K
- Viiv Healthcare Company$161
- Daiichi Sankyo Inc.$113
- Medtronic$65
- Gilead$49
- Nestle Healthcare Nutrition Inc.$37
- plus $115 from 6 others
What the payments were for
- Speaking & faculty fees$2,48281%
- Food & beverage$59519%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Organon | 6 | $2,537 |
| Viiv Healthcare Company | 2 | $161 |
| Daiichi Sankyo Inc. | 1 | $113 |
| Medtronic | 2 | $65 |
| Gilead | 1 | $49 |
| Nestle Healthcare Nutrition Inc. | 2 | $37 |
| Dynavax Technologies Corporation | 1 | $22 |
| Bayer | 1 | $22 |
| GSK | 1 | $21 |
| Merck | 1 | $19 |
| Shield Therapeutics Inc | 1 | $18 |
| Dexcom, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NEXPLANON$2,482
- CABENUVA$125
- INJECTAFER$113
How this compares
$3,077 in reported general payments places this provider in the 85th percentile of 1,153 acute care providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Epinephrine | 12 | $4,048 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $892 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 28 | $782 |
| Lisinopril | 25 | $274 |
| Atorvastatin Calcium | 33 | $241 |
| Diclofenac Sodium | 13 | $239 |
| Metformin Hcl | 28 | $219 |
| Tamsulosin Hcl | 15 | $207 |
| Gabapentin | 15 | $185 |
| Levothyroxine Sodium | 13 | $164 |
| Amlodipine Besylate | 25 | $148 |
| Pantoprazole Sodium | 15 | $146 |
| Losartan Potassium | 18 | $131 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 11 | $92 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 18 | $89 |
Paid to pharmacies, not to this prescriber.
Other acute care in Bakersfield
- Leslie PetersenCamarillo$370K
- Joyce KhremianSan Dimas$73K
- Eleanor VierraSacramento$64K
- Frances DyLos Angeles$57K
- Savannah HarrisVentura$56K
- Kori Ann JohnstonLos Angeles$42K
- Caroline KwongOrange$42K
- Gregory KnutzenColton$41K
- Sunita BoparaiLos Angeles$37K
- Sherona BauLos Angeles$32K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.